Latest News and Press Releases

Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma’s continued maturation as the...

Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 points on top of Standard of Care (“SoC”) at 6 weeksDurable effects...

In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release...

Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference:...

- Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events -- Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder...

Ex-presidente da empresa farmacêutica especializada da Shire PLC ("Shire"), com mais de 30 anos de experiência em neurociência, doenças raras e produtos farmacêuticos especializados, incluindo cargos...

Mantan Presiden bisnis Farmasi Spesialis di Shire PLC (“Shire”), dengan pengalaman lebih dari 30 tahun di bidang neurosains, penyakit langka, dan farmasi spesialis, termasuk posisi pemimpin senior di...

• נשיא לשעבר של עסקי התרופות הייעודיות של Shire PLC ("Shire"), עם יותר מ-30 שנות ניסיון בתחומי מדעי המוח, מחלות נדירות ותרופות ייעודיות, כולל תפקידי ניהול בכירים ב-Astra-Merck ו-AstraZeneca PLC •...

Er ist ehemaliger President des Spezialpharmazeutika-Geschäftsbereichs von Shire PLC („Shire“) mit über 30 Jahren Erfahrung auf dem Gebiet von Neurowissenschaften, seltenen Erkrankungen und...

Ancien président de la division pharmaceutique spécialisée de Shire PLC (« Shire »), il cumule plus de 30 ans d’expérience dans les domaines des neurosciences, des maladies rares et des produits...